Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
The phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk l…